Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.02 – $0.06
36% from low
Exchange
OTC Link
CS
Borrow rate
17.87%
Hard to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $36.6K | $58.7K | $121.9K | $32.4K | $75.6K | $82.4K | $135.1K | $41.4K |
| Cost of revenue | $414.7K | $43.8K | $720.0K | $9.8K | $149.2K | $42.2K | $0 | $0 |
| Gross profit | −$378.0K | $14.8K | −$598.1K | $22.6K | −$73.7K | $40.2K | $135.1K | $41.4K |
| Gross margin | -1032.6% | 25.3% | -490.5% | 69.8% | -97.5% | 48.7% | 100.0% | 100.0% |
| R&D | $0 | $0 | $0 | $0 | $0 | $485.0K | $419.7K | $173.2K |
| Operating income | −$481.4K | −$62.6K | −$999.5K | −$2.9M | −$1.9M | −$2.1M | −$1.6M | −$1.3M |
| EBITDA | −$1.1M | −$59.5K | −$999.5K | −$4.0M | −$4.8M | −$2.1M | −$1.6M | −$1.7M |
| Net income | −$1.1M | −$62.6K | −$999.5K | −$4.3M | −$6.3M | −$2.1M | −$1.6M | −$1.7M |
| Net margin | -3090.3% | -106.6% | -819.7% | -13341.4% | -8391.9% | -2556.4% | -1207.1% | -4059.9% |
| EPS (diluted) | -0.02 | -0.00 | -0.02 | -0.06 | -0.07 | -0.02 | -0.01 | -0.01 |
Annual figures · source: Financial Modeling Prep
CARDIAC BIOTECH SOLUTION
No one on the platform currently holds CBSC.
No tracked institution reports a position in CBSC as of their last filing.
No one on the platform has traded CBSC yet.
| $47M |
| — |
| LIFDLFTD Partners Inc. | $0.16 | +0.00% | $2M | — |
| RMSLREMSleep Holdings, Inc. | $0.00 | -4.17% | $4M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 111.9× sales vs its 297.9× historical median P/S.
Fair value ≈ $0.09 · price $0.03 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.